

Biotechnology UltraSector ProFund

Investor Class BIPIX



Semi-annual Shareholder Report – January 31, 2026

Fund Overview

This Semi-annual shareholder report contains important information about the Biotechnology UltraSector ProFund (the "Fund") for the period of August 1, 2025 to January 31, 2026. You can find additional information about the Fund at <https://www.profund.com/literature>. You can also request this information by contacting us at 888-776-3637.

What were the Fund's costs for the last six months?

(based on a hypothetical \$10,000 investment)

Class Name	Costs of a \$10,000 investment	Costs paid as a percentage of a \$10,000 investment
Investor Class	\$97	1.41%

Fund Statistics

Net Assets	\$176,253,242
Number of Holdings*	151
Net Investment Advisory Fees	\$418,630
Portfolio Turnover	45%

* No. of Holdings excludes any derivatives and collateral for securities loaned.

Largest Sector Weights

Sector	Weight
Biotechnology	100%

Market Exposure

Investment Type	% of Net Assets
Equity Securities	76%
S&P Biotechnology Select Industry Index Swap Agreements	75%
Total	151%

Largest Equity Holdings

Holding	% of Net Assets
Moderna, Inc.	1.4%
Mirum Pharmaceuticals, Inc.	1.2%
REVOLUTION Medicines, Inc.	1.2%
Vaxcyte, Inc.	1.1%
Amicus Therapeutics, Inc.	1.1%

"Market Exposure" includes the value of total investments (including the contract value of any derivatives) and excludes any short-term investments and instruments used for cash management.

Biotechnology UltraSector ProFund

Investor Class BIPIX

Semi-annual Shareholder Report – January 31, 2026

Additional information about the Fund including the Financial Statements, Prospectus and Statement of Additional Information is available: On the Fund's website, <https://www.profund.com/literature>, or upon request, by calling 888-776-3637.

